The Tumour-Suppressive Role of Myosin Heavy Chain 9 (MYH9) in Oral Squamous Cell Carcinoma

Evolution of polymer formation within the actin superfamily

10.1091/mbc.e15-11-0778 · doi-reference

Myosin II dynamics and cortical flow during contractile ring formation in Dictyostelium cells

10.1083/jcb.200011013 · doi-reference

TTK defines a high-risk oral squamous cell carcinoma subtype through dual mTORC1/NF-κB activation

10.1016/j.identj.2025.103945 · doi-reference

Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis

10.7150/thno.46001 · doi-reference

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma

10.1038/ng.3905 · doi-reference

Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9

10.1038/s41392-019-0084-3 · doi-reference

ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK

10.1186/s13046-023-02904-w · doi-reference

Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway

10.1038/s41420-022-00933-6 · doi-reference

Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/NOTCH/ DDR axis in pancreatic ductal adenocarcinoma

10.1038/s41419-024-07110-w · doi-reference

The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma

10.1038/s41392-024-01963-5 · doi-reference

LncRNA AFAP1-AS1 promotes oral squamous cell carcinoma development by ubiquitin-mediated proteolysis

10.1016/j.identj.2024.04.024 · doi-reference

MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling

10.1038/s41420-021-00681-z · doi-reference

NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway

10.18632/aging.204377 · doi-reference

MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway

10.1038/s41598-025-87151-z · doi-reference

The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer

10.18632/oncotarget.14967 · doi-reference

Role of myosin heavy chain 9 in gastrointestinal tumorigenesis: a comprehensive review

10.4251/wjgo.v17.i6.106617 · doi-reference

A key protein involved in tumor progression and virus-related diseases

10.1016/j.biopha.2023.116118 · doi-reference

PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9

10.1016/j.omto.2022.08.003 · doi-reference

Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents

10.1038/s41392-020-00430-1 · doi-reference

Regulating tumor suppressor genes: post-translational modifications

10.1038/s41392-020-0196-9 · doi-reference

Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function

10.1016/j.drup.2021.100770 · doi-reference

EZH2-mediated downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells

10.1158/0008-5472.can-20-0458 · doi-reference

Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness, drug resistance and metastasis via regulating RABIF/MMP signaling in triple negative breast cancer

10.3390/cells10102524 · doi-reference

Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma

10.1016/j.oraloncology.2013.01.003 · doi-reference

Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: implications of alternative treatment strategies

10.1002/hed.24803 · doi-reference

p22phox confers resistance to cisplatin, by blocking its entry into the nucleus

10.18632/oncotarget.2893 · doi-reference

MYH9 suppresses melanoma tumorigenesis, metastasis and regulates tumor microenvironment

10.1007/s12032-020-01413-6 · doi-reference

Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

10.1126/science.1248627 · doi-reference

Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review

10.1186/s12964-024-01781-w · doi-reference

MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis

10.1002/cbin.11894 · doi-reference

Clinicopathological significance of NMIIA overexpression in human gastric cancer

10.3390/ijms131115291 · doi-reference

Myosin heavy chain 9: oncogene or tumor suppressor gene?

10.12659/msm.912320 · doi-reference

Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome)

10.1182/blood.v97.4.1147 · doi-reference

Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly

10.1038/79069 · doi-reference

In vivo studies on nonmuscle myosin II expression and function in heart development

10.2741/3942 · doi-reference

Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis

10.1091/mbc.e10-04-0293 · doi-reference

Current trends of targeted therapy for oral squamous cell carcinoma

10.1007/s00432-022-04028-8 · doi-reference